Researchers say this is the first combination therapy that targets two different cancer survival mechanism: PARP and WNT signaling.

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...

Researchers at the University of Colorado Cancer Center have discovered a novel therapy combination that could offer new hope ...

Researchers have uncovered a specific form of epigenetic aging that leads to the shutdown of key genes in intestinal stem ...

Researchers from the Leibniz Institute on Aging - Fritz Lipmann Institute (FLI) in Jena, Germany, the Molecular Biotechnology ...

The acquisition of Enci Therapeutics will advance Innova Therapeutics' lead program, IVT-8086, a humanized monoclonal antibody targeting SFRP2 which is expressed in most solid and hematological ...

FDA fast track designation facilitates expedited development of DPTX3186, recognizing its potential to address serious unmet ...

Parabilis Medicines, a clinical-stage biopharmaceutical company committed to creating extraordinary medicines for people living with cancer, today announced preliminary clinical data demonstrating the ...

Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, ...

Heidelberg University has been successful in the current approval round of the German Research Foundation (DFG) with three grant applications for major research consortia. For the three Collaborative ...